ProKidney Corp. (PROK)
NASDAQ: PROK · Real-Time Price · USD
2.180
+0.030 (1.40%)
At close: Jan 22, 2026, 4:00 PM EST
2.220
+0.040 (1.83%)
After-hours: Jan 22, 2026, 6:12 PM EST
ProKidney Revenue
ProKidney had revenue of $217.00K in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $744.00K. In the year 2024, ProKidney had annual revenue of $76.00K.
Revenue (ttm)
$744.00K
Revenue Growth
n/a
P/S Ratio
913.82
Revenue / Employee
$3,647
Employees
204
Market Cap
655.82M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 76.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rigel Pharmaceuticals | 282.08M |
| Fulcrum Therapeutics | 80.00M |
| Invivyd | 50.04M |
| Gossamer Bio | 44.05M |
| MeiraGTx Holdings | 27.42M |
| LENZ Therapeutics | 17.50M |
| Evommune | 13.00M |
PROK News
- 8 days ago - ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 16 days ago - ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates - GlobeNewsWire
- 2 months ago - ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025 - GlobeNewsWire
- 3 months ago - ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference - GlobeNewsWire
- 3 months ago - ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2025 - GlobeNewsWire
- 4 months ago - ProKidney: Slow-Burning 'Buy' Opportunity Based On 2027 Approval Of Kidney Disease Therapy - Seeking Alpha
- 4 months ago - ProKidney Corp. (PROK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha